2025 Asia-Pacific Cancer Gene Therapy Market Revenue Opportunities Report
Description
The 2025 Asia-Pacific Cancer Gene Therapy Market Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Cancer Gene Therapy Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the Asia-Pacific cancer gene therapy market include Novartis AG, Gilead Sciences (via its subsidiary Kite Pharma), bluebird bio, Inc., and BioRay Pharmaceuticals. Novartis AG and Kite Pharma lead in gene therapies for cancer, leveraging advanced research, clinical trials, and strong R&D infrastructure across Asia-Pacific. Bluebird bio focuses on innovative viral vector-based gene therapies and has presence in key Asia-Pacific markets. BioRay Pharmaceuticals, based in China, is a significant regional player developing novel antibody therapeutics and biosimilars with extensive product approvals and strong local manufacturing capabilities.
These companies are supported by favorable government regulations, increasing cancer incidence, and growing investment in gene therapy R&D within the region. The Asia-Pacific market is rapidly expanding with an expected CAGR of approximately 18.7-19% through 2030, driven by innovative therapies such as oncolytic virotherapy and CRISPR-based editing platforms. Local players like BioRay Pharmaceuticals complement global giants by focusing on autoimmune and cancer-related biologics, accelerating access to advanced treatments in Asia-Pacific nations including China, Japan, South Korea, and India.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Cancer Gene Therapy Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the Asia-Pacific cancer gene therapy market include Novartis AG, Gilead Sciences (via its subsidiary Kite Pharma), bluebird bio, Inc., and BioRay Pharmaceuticals. Novartis AG and Kite Pharma lead in gene therapies for cancer, leveraging advanced research, clinical trials, and strong R&D infrastructure across Asia-Pacific. Bluebird bio focuses on innovative viral vector-based gene therapies and has presence in key Asia-Pacific markets. BioRay Pharmaceuticals, based in China, is a significant regional player developing novel antibody therapeutics and biosimilars with extensive product approvals and strong local manufacturing capabilities.
These companies are supported by favorable government regulations, increasing cancer incidence, and growing investment in gene therapy R&D within the region. The Asia-Pacific market is rapidly expanding with an expected CAGR of approximately 18.7-19% through 2030, driven by innovative therapies such as oncolytic virotherapy and CRISPR-based editing platforms. Local players like BioRay Pharmaceuticals complement global giants by focusing on autoimmune and cancer-related biologics, accelerating access to advanced treatments in Asia-Pacific nations including China, Japan, South Korea, and India.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
